Hepion Pharmaceuticals(CTRVP)

Focus: Hepion Pharmaceuticals is a public-stage antiviral biotech focused on infectious diseases and neurology, headquartered in Edison, NJ with a pipeline targeting NASH and hepatitis B.

Infectious Diseases Neurology

Profile data last refreshed 19h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Hepion Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow Hepion Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthSolid

Pipeline

Early-stage

5 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

CRV431

Hepatitis B

PHASE_1

Clinical Trials (1)

NCT03596697A Study in Healthy Volunteers

Phase 1

Help build intelligence for Hepion Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage public company with 5 active clinical programs across Phase 1-2, offering exposure to drug development from mid-stage onwards
Focus on NASH and hepatitis B addresses large unmet medical needs in high-prevalence indications
Recently founded (2024) as public entity suggests potential for rapid scaling and organizational growth opportunities

Watch Out For

Critical cash burn: $48.9M net loss in FY 2024 with only $406K cash on hand in FY 2025 raises immediate solvency concerns
Zero active job openings and no disclosed headcount suggest minimal hiring and potential restructuring risk
No marketed products, no revenue, and no Phase 3 programs means earliest realistic commercialization is 2-3+ years away with high clinical failure risk

Generated by Claude from Hepion Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

[14C]-rencofilstat 225mg

NASH With Fibrosis

PHASE_1

Clinical Trials (1)

NCT05737433Single Dose ADME Study of [14C]-Rencofilstat in Healthy Male Subjects

Phase 1

CRV431 75mg

NASH - Nonalcoholic Steatohepatitis

PHASE_2

Clinical Trials (1)

NCT04480710A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects

Phase 2

Rencofilstat

Nonalcoholic Steatohepatitis (NASH)

PHASE_2

Clinical Trials (1)

NCT05402371A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis

Phase 2

rencofilstat, 75 mg

NASH With Fibrosis

PHASE_2

Clinical Trials (1)

NCT05461105A Study to Evaluate the Safety and Efficacy of Rencofilstat in Adult Subjects With NASH F3

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2024

Portfolio: 5 clinical trials

Top TAs: Metabolic Diseases, Gastroenterology, Infectious Diseases

Publications: 14 in PubMed

SEC Filings: 2 available

Therapeutic Area Focus

Metabolic Diseases

4 pipeline

Gastroenterology

3 pipeline

Infectious Diseases

3 pipeline

Marketed

Pipeline

Financials (FY2025)

R&D Spend

$12M67%

Net Income

-$13M

Cash

$406K

Source: SEC 10-K Filing

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Cyclophilin Inhibitor Rencofilstat Combined with Proteasome Inhibitor Ixazomib Increases Proteotoxic Cell Death in Advanced Prostate Cancer Cells with Minimal Effects on Non-Cancer Cells.

Biomedicines

2025

PMID:41153724

A Novel Chemotherapy Combination to Enhance Proteotoxic Cell Death in Hepatocellular Carcinoma Experimental Models Without Killing Non-Cancer Cells.

International journal of molecular sciences

2025

PMID:40724949